Cargando…
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
We aim to elucidate the prognostic value of PIK3CA mutations and copy number (CN) gain (PIK3CA-mut/gain) in hormone receptor-positive and HER2-negative (HR + /HER2−) breast cancer (BC). We analyzed primary HR + /HER2− BC from three publicly available datasets comprising over 2000 samples and assesse...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857304/ https://www.ncbi.nlm.nih.gov/pubmed/35181669 http://dx.doi.org/10.1038/s41523-022-00382-5 |
_version_ | 1784654013444128768 |
---|---|
author | Migliaccio, Ilenia Paoli, Marta Risi, Emanuela Biagioni, Chiara Biganzoli, Laura Benelli, Matteo Malorni, Luca |
author_facet | Migliaccio, Ilenia Paoli, Marta Risi, Emanuela Biagioni, Chiara Biganzoli, Laura Benelli, Matteo Malorni, Luca |
author_sort | Migliaccio, Ilenia |
collection | PubMed |
description | We aim to elucidate the prognostic value of PIK3CA mutations and copy number (CN) gain (PIK3CA-mut/gain) in hormone receptor-positive and HER2-negative (HR + /HER2−) breast cancer (BC). We analyzed primary HR + /HER2− BC from three publicly available datasets comprising over 2000 samples and assessed the associations with tumoral and clinical characteristics and outcome. Clinical benefit (CB) in alpelisib-treated patients from two studies including 46 patients was analyzed. About 8–10% of HR + /HER2− primary BC had PIK3CA-mut/gain. In two of the datasets analyzed, among patients with PIK3CA mutant tumors, those with mut/gain had significantly worse outcome compared to those with CN neutral (PIK3CA-mut/neut) and PIK3CA-mut/gain remained an independent prognostic factor. CB of alpelisib-treated patients with PIK3CA-mut/gain and PIK3CA-mut/neut tumors was comparable. PIK3CA CN might help clarifying the prognostic and predictive role of PIK3CA mutations. Further studies are warranted. |
format | Online Article Text |
id | pubmed-8857304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-88573042022-03-03 PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer Migliaccio, Ilenia Paoli, Marta Risi, Emanuela Biagioni, Chiara Biganzoli, Laura Benelli, Matteo Malorni, Luca NPJ Breast Cancer Article We aim to elucidate the prognostic value of PIK3CA mutations and copy number (CN) gain (PIK3CA-mut/gain) in hormone receptor-positive and HER2-negative (HR + /HER2−) breast cancer (BC). We analyzed primary HR + /HER2− BC from three publicly available datasets comprising over 2000 samples and assessed the associations with tumoral and clinical characteristics and outcome. Clinical benefit (CB) in alpelisib-treated patients from two studies including 46 patients was analyzed. About 8–10% of HR + /HER2− primary BC had PIK3CA-mut/gain. In two of the datasets analyzed, among patients with PIK3CA mutant tumors, those with mut/gain had significantly worse outcome compared to those with CN neutral (PIK3CA-mut/neut) and PIK3CA-mut/gain remained an independent prognostic factor. CB of alpelisib-treated patients with PIK3CA-mut/gain and PIK3CA-mut/neut tumors was comparable. PIK3CA CN might help clarifying the prognostic and predictive role of PIK3CA mutations. Further studies are warranted. Nature Publishing Group UK 2022-02-18 /pmc/articles/PMC8857304/ /pubmed/35181669 http://dx.doi.org/10.1038/s41523-022-00382-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Migliaccio, Ilenia Paoli, Marta Risi, Emanuela Biagioni, Chiara Biganzoli, Laura Benelli, Matteo Malorni, Luca PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer |
title | PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer |
title_full | PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer |
title_fullStr | PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer |
title_full_unstemmed | PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer |
title_short | PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer |
title_sort | pik3ca co-occurring mutations and copy-number gain in hormone receptor positive and her2 negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857304/ https://www.ncbi.nlm.nih.gov/pubmed/35181669 http://dx.doi.org/10.1038/s41523-022-00382-5 |
work_keys_str_mv | AT migliaccioilenia pik3cacooccurringmutationsandcopynumbergaininhormonereceptorpositiveandher2negativebreastcancer AT paolimarta pik3cacooccurringmutationsandcopynumbergaininhormonereceptorpositiveandher2negativebreastcancer AT risiemanuela pik3cacooccurringmutationsandcopynumbergaininhormonereceptorpositiveandher2negativebreastcancer AT biagionichiara pik3cacooccurringmutationsandcopynumbergaininhormonereceptorpositiveandher2negativebreastcancer AT biganzolilaura pik3cacooccurringmutationsandcopynumbergaininhormonereceptorpositiveandher2negativebreastcancer AT benellimatteo pik3cacooccurringmutationsandcopynumbergaininhormonereceptorpositiveandher2negativebreastcancer AT malorniluca pik3cacooccurringmutationsandcopynumbergaininhormonereceptorpositiveandher2negativebreastcancer |